Caxton Associates (New York)’s BridgeBio Pharma BBIO Stock Holding History

Caxton Associates (New York)’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,843	Closed	-$207K	–	466
2023 Q3	$207K	Buy	+7,843	New	+$223K	0.03%	356

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caxton Associates (New York)'s BBIO Position: Q4 2023 in Review

Caxton Associates (New York) sold out of BridgeBio Pharma (BBIO) in Q4 2023, closing a stake of 7,843 shares — an estimated $207K sold.

Caxton Associates (New York) first reported a position in BBIO in Q3 2023 and held it in 1 quarter. The position peaked at $207K in Q3 2023. 247 funds tracked by Wall St. Rank hold BBIO as of Q4 2023.

Caxton Associates (New York) reported no remaining BridgeBio Pharma position as of Q4 2023 after selling out during the quarter.
Caxton Associates (New York) sold 7,843 BridgeBio Pharma shares in Q4 2023, an estimated $207K.
Caxton Associates (New York) first reported a position in BridgeBio Pharma in Q3 2023 and held it in 1 quarter.
Caxton Associates (New York)'s BridgeBio Pharma position peaked at $207K in Q3 2023.
247 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2023.

Based on Caxton Associates (New York)'s 13F filing for Q4 2023, filed 14 Feb 2024.